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abstract: Although the exact mechanisms that lead to shallow invasion or defective trophoblastic differentiation in pre-eclampsia are
still unknown, it is widely admitted that the etiology of pre-eclampsia is a defect in trophoblast invasion of the uterine spiral arteries. We have
previously observed that the status of a chaperone protein, glucose regulated protein 78 (GRP78) is associated with the invasive properties of
cytotrophoblastic cells; we therefore hypothesized that circulating GRP78 could serve as a diagnostic tool in pre-eclampsia. In a prospective
case–control study, we quantiﬁed GRP78 autoantibodies, complexes of GRP78 with autoantibodies and GRP78 (C-term fragment, N-term
fragment and full-length GRP78) by ELISA. Plasma from women diagnosed with pre-eclampsia (n ¼ 16), from women during the ﬁrst trime-
ster of pregnancy who subsequently developed pre-eclampsia (n ¼ 10) and from healthy pregnant women (controls, n ¼ 58 at term, n ¼ 26
at ﬁrst trimester) were analysed and compared. We observed no signiﬁcant difference between pre-eclamptic and healthy pregnant women
for autoantibodies-GRP78 complexes or total GRP78 at both ﬁrst trimester and at delivery. In contrast, the ratio of C-terminal GRP78 over
full length GRP78 was signiﬁcantly different in plasma of pre-eclamptic patients as compared with controls both during ﬁrst trimester (P,
0.004) and at term (P, 0.0001). Our ﬁndings suggest that circulating C-terminal GRP78 reﬂect the invasive properties of cells, and could be
used as a predictive marker for pre-eclampsia early in pregnancy.
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Introduction
Multiple pathophysiological factors are known to contribute to the
classic conceptual model describing pre-eclampsia (PE) as a two-stage
process: (1) abnormal placentation and vascular remodelling, and (2) a
subsequent maternal syndrome characterized by endothelial injury and
activation. The ﬁrst stage of PE has been postulated to be that of a
reduced uteroplacental perfusion resulting from an abnormal cytotro-
phoblast invasion of spiral arterioles (Robertson et al., 1967; Gerretsen
et al., 1981). Placental ischemia/hypoxia leads to widespread acti-
vation/dysfunction of the maternal vascular endothelium which in
turn will cause hypertension by impairing renal function and increasing
total peripheral resistance, characteristic of the second-stage of this
syndrome.
Mechanisms that lead to shallow invasion or that govern trophoblas-
tic differentiation in PE are still unknown but it has been suggested that
factors involved in regulating trophoblast invasion could be used as
early markers of PE. Indeed several studies described modiﬁed activi-
ties of circulating metalloproteinases 2 and 9 in patients with PE
compared with controls (Narumiya et al., 2001; Pang and Xing,
2003; Myers et al., 2005). However, quantiﬁcation of these proteolytic
activities depends on pre-analytic conditions that make these tests
impractical in clinical settings (Meisser et al., 2005).
Our group recently observed the presence of an endoplasmic
reticulum (ER) stress protein, glucose-regulated protein 78 (GRP78),
on the cell surface of invasive cytotrophoblastic (CTB) cells (unpub-
lished data) as described in some cancer cells (Shin et al., 2003). In
cancer cells, overexpression of GRP78 has been shown to be corre-
lated to the in vitro invasive properties of the cells and the in vivo
metastasis potential (Fu and Lee, 2006; Zhang et al., 2006). The pres-
ence of GRP78 on cell surface of highly metastatic cancer cells tends to
suggest that it may mediate signal transduction pathways that induce
proliferation and invasion. Given the importance of over-expression
of GRP78 in cancer cell survival and its speciﬁc localization on the
cell surface of invasive cells, this protein represents a potential prog-
nostic factor and an important therapeutic target. Since the discovery
of circulating GRP78 and autoantibodies against GRP78 by Castelli and
Delpino (2002) in the peripheral circulation of healthy patient,
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circulating GRP78 was evaluated as potent biomarker of cancer. High
levels of circulating autoantibodies against GRP78 were observed in
prostate cancer patients. These autoantibodies can bind to and stimu-
late proliferation of tumour cells bearing GRP78 on their cell surface.
They could by used as biomarker of aggressive tumour behaviour.
Cleavage products of GRP78 were also demonstrated in hepatoma
cell lines and sera of patients with hepatocarcinoma (HCC) leading the
authors to suggest that speciﬁc isoforms in general and cleavage pro-
ducts in particular should therefore be further evaluated as new
markers for HCC.
In the current study, we hypothesized that GRP78, GRP78 cleavage
products, or GRP78 autoantibodies could be used as a marker of
defective placental invasion and could be used as an early diagnostic
marker of the abnormal placentation characteristic of PE.
Materials and Methods
After Institutional Review Board approval, written informed consent was
obtained from term healthy pregnant women (n ¼ 58, controls) and
women diagnosed with PE according to ACOG criteria (n ¼ 16).
Sera collection
Sera were collected from all women (n ¼ 74) at the time of delivery.
Furthermore, we obtained sera (stored at 2208C, in the serum bank of
the Hormone laboratory) taken for a trisomy 21 screening between
10 and 14 weeks gestation from women who were subsequently
diagnosed with PE (n ¼ 10) and compared with control sera (n ¼ 26).
Anti-GRP78 ELISA
Ninety-six-well microplates (Immunosorp, Nunc, Nalge Nunc Inter-
national, Rochester, NY, USA) were coated with 10 mg/ml human recom-
binant GRP78 (Stressgen, Lubioscience, Switzerland) in 0.1 M NaHCO3,
pH 9.6. Non-speciﬁc binding was blocked by the addition of 3% bovine
serum albumin (BSA) in phosphate-buffered saline (PBS). One hundred
microlitre of 1/500 and 1/1000 diluted serum or 100 ml of PBS–BSA
used as blank were added to the wells and the plate incubated overnight
at 48C. Following four washes with PBS/0.1% Tween 20, detection anti-
body (goat anti-human IgG-horse radish peroxidase (Dako) diluted 1/
12000 in PBS–BSA was added to each well at room temperature (RT),
for 2 h. The plates were developed with 3,30,5,50-tetramethylbenzidine
(TMB) (R&D biosystem). Plates were read at 450 nm. A reference
serum was diluted (1/100; 1/200; 1/400; 1/600; 1/800; 1/1000; 1/
1200) and used to construct a standard curve. Results (mean of two
wells) were obtained by comparison to this curve and given in multiple
of this reference. The intra- and inter-assay coefﬁcients of variation for
this ELISA were 8.79 and 9.03%, respectively.
Complexes anti-GRP78/GRP78 ELISA
ELISA plates were coated with antibodies against GRP78 (N-20 from Santa
Cruz for N-terminus GRP78 or GL-19 from Sigma for C-terminus GRP78)
in 0.1 M NaHCO3, pH 9.6. Non-speciﬁc binding was blocked by the
addition of PBS–BSA. One hundred microlitre of 1/500 and 1/1000
diluted serum or 100 ml of PBS–BSA used as blank were added to the
wells and the plate incubated overnight at 48C. Following four washes
with PBS/0.1% Tween 20, detection antibody (goat anti-human IgG-horse
radish peroxidase (Dako) diluted 1/12000 in PBS–BSA was added to each
well at RT, for 2 h. The plates were developed with TMB and read at
450 nm. A reference serum was diluted (1/100; 1/200; 1/400; 1/600;
1/800; 1/1000; 1/1200) and used to construct a standard curve.
Results (mean of two wells) were obtained by comparison to this curve
and given in multiple of this reference. The intra- and inter-assay coefﬁ-
cients of variation were 5.99 and 8.32%, respectively, for the ELISA
anti-GRP78/N-terminus GRP78, and 5.85 and 6.43%, respectively, for
the ELISA anti-GRP78/C-terminus GRP78.
Grp78 ELISA
ELISA plates were coated with antibodies against GRP78 C-terminus
(GL-19 from Sigma) in 0.1 M NaHCO3, pH 9.6. Non-speciﬁc binding
was blocked by the addition of PBS–BSA. One hundred microlitre of
serum or PBS–BSA used as blank were added and the plate incubated
overnight at 48C. Following four washes with PBS/0.1% Tween 20, a sec-
ondary antibody recognizing the KDEL sequence in the C terminal region
(Stressgen, diluted 1/300 in PBS–BSA) was incubated 2 h, at RT. To
detect full length (FL) GRP78, a secondary antibody recognizing
N-terminal part of GRP78 (N-20, diluted 1/300 in PBS–BSA) was used.
Following four washes with PBS/0.1% Tween 20, detection antibody
(secondary antibody conjugated to horse radish peroxidase (Dako)
diluted 1/12000 in PBS–BSA) was added to each well. The plates were
developed with TMB, and read at 450 nm. A reference serum was
chosen and incorporated into each assay to allow meaningful comparisons
between different experiments. The intra- and inter-assay coefﬁcients of
variation were 9.47 and 10%, respectively, for the C-terminus GRP78
ELISA, and 8.9 and 9.46%, respectively, for the FL-GRP78 ELISA.
CTB puriﬁcation
Placental tissue was obtained from patients undergoing a legal abortion
during the ﬁrst trimester (7–12 weeks of gestation). Informed written
consent was obtained from all patients before their inclusion in the
study, for which approval was obtained from the local ethics committee.
CTB were isolated from ﬁrst trimester placentas and immunopuriﬁed
(by negative adsorption on immobilized CD45 antibodies) as described
elsewhere (Bischof et al., 1995) and grown in Dulbecco’s minimal essential
medium high glucose/F-12 containing 10% fetal bovine serum and anti-
biotics (100 U/ml penicillin, 100 mg/ml streptomycin) at 378C in a humidi-
ﬁed 5% CO2 atmosphere. Purity of the ﬁnal cells preparation was
evaluated by immunocytochemistry using cytokeratin-7 as a marker of
CTB cells and vimentin as a marker for non-epithelial cells. Less than
5% of the cells stained for vimentin, and 95% were cytokeratin 7 positive.
FACS analysis
Expression of cell-surface GRP78 was analysed by immunoﬂuorescence on
a FACSCalibur (BD Biosciences, San Jose, CA, USA). Acquisition and
analysis were performed using BD CellQuestTM Pro (BD Biosciences).
Labelling with GL-19 (dilution 1/200), or N-20 (dilution 1/50) antibodies
was visualized by using FITC-conjugated secondary antibody. In each
immunoﬂuorescence experiment an isotype-matched IgG antibody was
used as a control and the ﬂuorescence intensity of stained cells was
gated according to established methods. The cell size (Forward angle
light scatter, FSC) and the cell density (908 light scatter, SSC) were simul-
taneously measured. Instrument settings were adjusted using control cells
to observe every event (cells and debris) in the dot-blot diagram.
Immunocytochemistry
Puriﬁed cells were seeded on a sterile labtek slide and placed at 378C in a
humidiﬁed 5% CO2 atmosphere during 24 h. Cells were washed with PBS
and ﬁxed with 3% paraformaldehyde (PFA), 15 min. Cells were then per-
meabilized or not with 0.2% triton in PBS (15 min, at RT). Non-speciﬁc
binding was blocked by incubation with fetal calf serum (10%) in PBS
(30 min, RT) before incubation of cells with primary antibody (dilution
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1/200 for GL-19 antibody, and 1/50 for N-20 antibody) for 1 h at RT.
Cells were then extensively washed with PBS, and incubated with second-
ary antibody (dilution 1/600) for 1 h at RT. The slides were washed again
and stained with diaminobenzidine chromogen system and counterstained
with Mayer’s hematoxylin solution (Sigma-Aldrich).
Cell-ELISA
CTB were seeded at 100 000 cells/well in a 96-well plate (Nunc, Roskilde,
Denmark) and incubated in culture medium for 24 h. Cells were then
washed, ﬁxed (3% PFA, 15 min, RT), washed again and permeabilized
(0.2% triton in PBS, 15 min) or not before adding primary antibodies
(dilution 1/200 for GL-19 or 1/50 for N-20, in culture medium) for
45 min, on a shaking platform, at 48C. The antibodies used were
anti-GRP78 (GL-19 and N-20), anti-KDEL, or anti-p53 (pAb1620). To
remove the unbound antibody, cells were washed four times in PBS–
BSA3%, and then incubated 30 min at 48C with horseradish peroxidase
conjugated secondary antibody. After incubation, cells were washed as
described above and the substrate 3,30,5,50-tetramethyl benzidine (R&D
systems, Minneapolis, USA) was added. The reaction was stopped by
adding 1 M sulphuric acid. Absorbance was read at 450 nm on a micro-
plate reader (Expert plus, Biochrom). Relative proportion of membrane
GRP78 was calculated by dividing absorbance of membrane GRP78 (non-
permeabilized cell-ELISA (CELISA)) over total GRP78 (permeabilized
CELISA).
Experiments were performed at least two times with different cell prep-
arations and run in triplicate.
Statistical analysis
Data were reported as mean þ standard deviation (SD). Student t test
was used to compare levels of soluble markers between controls and pre-
eclamptic women. Receiver Operating Characteristics (ROC) curves,
applied to the ﬁrst and third trimester data, were used to calculate the
area under the curve for the ratio C-term GRP78/full-length GRP78
and to ﬁnd the best cut-off point for these parameters to calculate their
diagnostic accuracy, sensitivity and speciﬁcity. The ROC curve is a
graphic representation of the relationship between the positives versus
false positives. Accuracy of a test is measured by the area under the
ROC curve and a diagonal. An area of one represents a perfect test
whereas an area of 0.5 estimates a worthless test.
Results
Demographic data were not different between the controls and pre-
eclamptic women in terms of parity, weight gain and body mass
index (BMI) (Table I). As expected, we did ﬁnd differences in gesta-
tional age at delivery and neonatal weight. In comparing clinical charac-
teristics at the time of ﬁrst trimester analysis, gestational age at the
time of blood test, maternal age or parity status was similar
between controls and women subsequently diagnosed with PE
(Table II).
First trimester levels of plasma autoantibodies/GRP78 complexes or
FL and C-terminal GRP78 were not different in healthy pregnant
women and women developing PE (Table III). In contrast, ﬁrst trimester
plasma levels of autoantibodies against GRP78 and the ratio of
C-terminal GRP78 to FL GRP78 were signiﬁcantly lower in patients
who later developed PE (P ¼ 0.033 and P ¼ 0.004, respectively).
The same parameters were signiﬁcantly altered in pre-eclamptic
women at the time of delivery, except that the ratio of C-terminal
GRP78 to FL GRP78 was signiﬁcantly increased in pre-eclamptic at
the time of delivery (Table IV).
Among healthy pregnant women (controls), GRP78 autoantibodies
also decreased with the progression of gestation. Along with this
decrease, a decrease in FL GRP78 was observed in controls and pre-
eclamptic women. C-terminal GRP78 did not change during gestation
in plasma of control patients; however, an important increase of this
part of GRP78 was found at the time of delivery in pre-eclamptic
women.
In order to evaluate the ability of autoantibodies and GRP78 to be
used as early markers to predict PE, ROC curves were constructed.
The area under the ROC curves for GRP78 autoantibodies was
0.664 for ﬁrst trimester and 0.689 for term (not shown). The clinical
sensitivities and speciﬁcities for these parameters were calculated from
ROC curves at the cut-off level (or criterion value) with the highest
accuracy (highest sensitivity and speciﬁcity combined). Early in preg-
nancy (ﬁrst trimester), at a cut off of 0.19, the GRP78 autoantibodies
yielded a sensitivity of 44.4% with a speciﬁcity of 80%. At the time of
delivery, the same parameter with a cut off of 0.5346 yielded a sensi-
tivity of 45.5% for a speciﬁcity of 79.5%.
The areas under the ROC curves for the ratio of C-terminal GRP78
over full-length GRP78 were 0.778 and 0.762 early in pregnancy (ﬁrst
trimester) and at the time of delivery, respectively. Early in pregnancy,
at a cut-off of 0.8273, the ratio of C-terminal GRP78 over FL GRP78
yielded a sensitivity of 100% with a speciﬁcity of 54.5%. At the time of
delivery the same parameter with a cut off of 1.9461 yielded a sensi-
tivity of 62.5% for a speciﬁcity of 89.7% (Fig. 1).
The presence of GRP78 on the membrane was conﬁrmed by
CELISA, FACS analysis and immunocytochemistry (Fig. 2). The
GRP78 antibody recognizing an N-terminal epitope failed to recognize
GRP78 on the CTB membrane by FACS analysis (Fig. 2A) suggesting
that it is the C-terminus of the transmembrane GRP78 that is in
the extracellular domain. This result is conﬁrmed by immunocyto-
chemistry since antibody recognizing N-terminal part of GRP78
.............................................................................................................................................................................................
Table I Demographic data of patients recruited at delivery
Pre-eclamptics (n 5 16) Controls (n5 58) P
Nullipara (%) 80 100 0.08
Weight gain (kg) 14.8+7.7 17.4+5.3 0.21
Pre-pregnancy BMI 31.9+7.5 29.2+4.6 0.23
Gestational age at delivery (weeks) 35.3+ 3.3 39+ 3.3 <0.0001
Neonatal weight (g) 2393.8+861 3038+890 0.008
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recognized GRP78 in permeabilized conditions (Fig. 2B, f) but not in
non-permeabilized conditions (Fig. 2B, e). CELISA experiments
reinforce these observations (Fig. 2C). The antibody pAb1620 was
used as negative control of CELISA experiment, the antibody recogniz-
ing KDEL domain localised in C-terminal part of GRP78 gave a weak
signal, whereas an intense signal was observed with the antibody
recognizing C-terminal part of GRP78 (Fig. 2C, a). KDEL and GL-19
antibodies recognise the C-terminal region but seems to react very
differently in this assay. That’s why relative proportion of membrane
GRP78 detected with different antibodies could be more signiﬁcant
than only membrane CELISA. The relative proportion of membrane
GRP78 recognized by N-20 antibody (13%) is signiﬁcantly lower
than that recognized by GL-19 antibody (68%) conﬁrming the pres-
ence of C-terminal part of membrane GRP78 in extracellular domain.
Discussion
Our ﬁndings demonstrated for the ﬁrst time that GRP78 autoanti-
bodies levels and the ratio of C-terminal GRP78 over FL GRP78 are
signiﬁcantly lower in plasma in the ﬁrst trimester of women who will
subsequently develop PE. Therefore, the ratio of C-terminal GRP78
over FL GRP78 could be an early diagnostic marker for PE.
Mechanisms that could explain this association include the pivotal
role of GRP78 as an ER chaperone protein belonging to the heat
shock protein 70 family. This protein, as the other members of its
family, plays an essential role in protein biosynthesis. It facilitates
folding and assembly of newly-synthesized proteins, and prevents
intra or intermolecular aggregation during stress conditions. GRP78
expression is induced by a variety of environmental and physiological
stress conditions which disturb ER function and homeostasis in
order to protect organs and tissue against apoptosis (Lee, 2001). Its
expression varies during developmental stages and among tissues
but it is mainly maintained at low basal level in almost all adult
tissues but is highly induced in most tumours (Dong et al., 2004; Li
an Lee, 2006). GRP78 is induced under conditions of hypoxia and
nutrient deprivation, explaining its high level in tumour cells (Lee,
2007) and in ﬁrst trimester trophoblastic cells (unpublished results).
GRP78 is generally believed to reside inside the ER lumen.
However, GRP78 is also found on the cell surface in a wide variety
of cancer cells, including neuroblastoma, lung adenocarcinoma,
colon adenocarcinoma, ovarian tumour cells (Shin et al., 2003), pros-
tate cancer (Mintz et al., 2003), proliferating endothelial cells, more
generally, stressed tumour cells (Davidson et al., 2005) and in ﬁrst tri-
mester trophoblastic cells. It is not known yet how GRP78 localizes to
the various cellular compartments and what is its physiological role on
the cell surface membrane, but we showed that membrane GRP78 of
trophoblastic cells is strongly associated with the invasive behaviour of
cells (unpublished results). Relocated on cell surface membrane,
GRP78 becomes present on the plasma membrane and its C-terminal
part in extracellular domain and could become accessible to proteo-
lytic cleavage. Circulating C-terminal fragment could be thus more
speciﬁc than GRP78 for detection of invasive properties of cells.
Therefore, the ratio of C-terminal GRP78 to FL GRP78 could reﬂect
the presence of membrane GRP78 and thus sign the invasive properties
of cells. This suggestion is in line with our ﬁnding of a decreased ﬁrst tri-
mester ratio of C-terminal GRP78 in the plasma of women who later
developed PE. Indeed, it is known that decreased ﬁrst trimester invasion
of trophoblast into the maternal spiral arteries could be a cause of PE. If
circulating C-terminal GRP78 reﬂects the invasive properties of cells, a
decreased ratio of C-terminal GRP78 to FL GRP78 would then reﬂect
defective placentation in women, which is concordant with our
ﬁnding in ﬁrst trimester sera. However, at term, C-terminal GRP78
and the ratio of C-terminal GRP78 to FL GRP78 were signiﬁcantly
increased in pre-eclamptic women. Overall, our ﬁndings suggest an
increase of proteolytic activity in plasma of pre-eclamptic women
........................................................................................
Table III Various ﬁrst trimester markers of PE
(mean+ SD)
PE (n 5 10) Control
(n 5 26)
t
Test
AutoAb 0.37+ 0.74 2.02+ 0.08 0.033
Complexes GRP78
C-term-AutoAb
1.25+0.11 1.06+0.08 0.217
Complexes GRP78
N-term-AutoAb
3.19+0.44 3.44+0.25 0.6
GRP78 C-term (AU) 0.226+0.022 0.257+0.016 0.157
GRP78 FL (AU) 0.315+0.033 0.307+0.017 0.412
GRP78 C-term/FL 0.724+ 0.025 0.842+ 0.027 0.004
Ab: antibodies; C/N-term: C/N-terminal; FL: full length; PE: pre-eclampsia; AU:
arbitrary unit.
........................................................................................
Table IV Various delivery markers of PE (mean+ SD)
At delivery PE (n 5 16) Control
(n5 58)
t Test
AutoAb 0.75+ 0.14 1.4+ 0.16 0.0057
Complexes GRP78
C-term-AutoAb
2.384+0.267 2.213+0.142 0.575
Complexes GRP78
N-term-AutoAb
2.80+0.65 3.56+0.43 0.346
GRP78 C-term (AU) 0.305+0.039 0.239+0.02 0.06
GRP78 FL (AU) 0.197+0.039 0.244+0.018 0.125
GRP78 C-term/FL 3.149+ 1.097 1.131+ 0.117 0.0007
Ab: antibodies; C/N-term: C/N-terminal; FL: full length; PE: pre-eclampsia; AU:
arbitrary unit.
........................................................................................
Table II Characteristics of patients recruited at ﬁrst
trimester of pregnancy
Pre-eclamptics
(n 5 10)
Controls
(n 5 26)
P
Nullipara (%) 87 61 0.14
Gestational age at the
time of sampling (weeks)
13.8+0.9 12.3+0.1 0.17
Maternal age (years) 27.4+1.3 29.3+0.8 0.21
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Figure 1 ROC curves analysis.
(A) First trimester. (B) Time of delivery.
Figure 2 Membrane localization of GRP78.
(A) FACS analysis of membrane GRP78. (a) cells stained with control antibody, (b) cells stained with GL-19 antibody, (c) cells stained with N-20
antibody. Lefthand plot shows FSC y axis and SSC x axis. Indicated percentage in righthand plot represents percentage of cells in R2 area (cells
which are positive for GRP78 antibody). (B) Immunocytochemistry of puriﬁed CTB in permeabilized conditions (a, b, d, f) or non-permeabilized con-
ditions (c, e). (a) cells stained with control goat antibody; (b) cells stained with control rabbit antibody; (c, d) cells stained with GL-19 antibody; (e, f)
cells stained with N-20 antibody. (C) Cell surface localization of GRP78 was analysed by CELISA. (a) GL-19 antibody, and KDEL antibodies were used
to detect membrane GRP78. PAb1620 antibody is directed against N-terminus of p53, and used here as a negative control. (b) Relative proportion of
membrane GRP78 (estimated by non-permeabilized CELISA) over total GRP78 (estimated by permeabilized CELISA) detected with GL-19 and N-20
antibodies. mb ¼ membrane.
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compared with healthy pregnant women that appears to allow or accel-
erate degradation of circulating GRP78 in pre-eclamptic women at
term. The biological signiﬁcance of this observation is still unknown
but interestingly some studies suggest a higher incidence of cancer in
womenwho developed PE (Paltiel et al., 2007), although this association
is debated (Terry et al., 2007). However, it would be noted that
the delivery time is signiﬁcantly lower in pre-eclamptic patients com-
pared with healthy patient and could also explain this observation
at delivery.
In conclusion, we demonstrate that the ratio of circulating C-
terminal GRP78 over FL GRP78 is lower in plasma of women who
will later be diagnosed with PE. This could be used as an early biologi-
cal marker of PE and might allow novel strategies early in pregnancy to
improve placentation before the consequences of defective tropho-
blastic invasion become irreversible. Our preliminary assessment of
circulating GRP78 constitutes a proof of principle rather than a deﬁni-
tive clinical study. Clearly the potential diagnostic potency of GRP78 in
asymptomatic women prone to develop PE remains to be established
and compared with known diagnostic parameters such as placental
protein 13 (Chafetz et al., 2007; Gonen et al., 2008; Huppertz
et al., 2008) for which ROC curves demonstrate an area of 0.91, a
90% speciﬁcity with 79% of sensitivity (Chafetz et al., 2007).
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